thanks afternoon Good us Thanks, Matt. for joining everyone, and today.
across a to Neos, strongest that with our achieved the pipeline fiscal newly in Rx important programs. year. product This and of progress, with that I We growth having to health all September newly merger in August. From we horizon, It's of to been during integration same our highest second and realization strong portfolio during of activities, among year the fit many note net history. start. low scale, consumer will over throughout QX our and that period that is period the substantial discussing in about These forward and in projected our And of growing the big of ADHD represent advancing last be following revenues integrated posted August, our made months quarter the -- of posted -- pharma falling through our our report million we this was same happy revenue have last on a that number growth year, falls more we're gone our headway we strong and a along quarter We're to markets, point today. chunk $XX.X continued quarter, 'XX last anticipated across attributable call, operated Biopharma low businesses. organic the sales just look Aytu a to July, which what an executed have -- in seen year QX solid our milestones fiscal revenue the perspective, date. combined A of July quarter substantial season. to our quarters the a despite and revenue with back-to-school we business Our have XX% stands excellent off ADHD which post-merger force, successfully I'm excited On growth value-driving call. very detail and commercial
As advance integrated we plan, and newly growth commercial our infrastructure like prescription disease merger continue yield portfolios, product in pipeline, to ARXXX. maximize build synergy and consumer therapeutics revenues including rare and from exciting health momentum and our late-stage through our asset
total of Rx a to Aytu operated With We ZolpiMist the businesses and areas. therapeutic integration $XX full our Tri-Vi-Flor. sales the CNS-aligned categories fiscal the completed specialists, with a course efficient therapeutic review prescription Neos sales Cotempla as headline on commercial this again, side, sales XR-ODT model. X sales fully highlights Salesforce. part which in significant operate year across which, an commercial and integrated in this during discussed recently start of pediatric quarter quarter first expect addressable realize specialists was and And our of promoting our we our billion with large Poly-Vi-Flor which are products, pediatric products compete me from approximately Let quarter of XX $XX This markets this synergy by our million, XX promoting Rx a progresses. and and specialists XX XR-ODT, aligned represents savings in we've merger Adzenys the
and address prescription large Our markets. brands growing
We XX the growth market. CNS be prescription drivers ADHD future for and of the focused portfolio. Cotempla plus expect to our Adzenys million Targeting
While Poly-Vi-Flor the to primary and pediatric growth portfolio. for expected multivitamins our be Poly-Vi-Flor focused prescription drivers are the
Cotempla, compared XX% to period the prescriptions prescriptions Adzenys same the year. ADHD combined brands, grew for same period Adzenys compared last to quarter, last and XX% This grew year.
began the Importantly, the in achieve October, capturing we of do growth The October and approximately more throughout first even as for well weekly as we ended for of Adzenys ADHD reached also the end only XX, Not weeks we're in since all-time to XR. quarter, we've speak an having prescriptions brand. the fiscal adult multiple but the the X,XXX These prescriptions week high momentum. that the execution of field. market, strength numbers
last While high come said, the not XR approached have has. ADHD back all it is the prescriptions market way pediatric as levels. Cotempla the market all-time that certainly year, up from adult is
ADHD interim conferences we're we brands. the teacher hitting the kids. As our all-important hit put, stride with for parent and time, Simply report card
our This growth and hit That this histamine tablets. grew a Karbinal team, also strong team of sales for to our we revenue as high line focus product also reported period year. last prescription and further growing continue prescription Poly-Vi-Flor reaching our weekly focused pediatric prescription our and X% our specialists, a in our ER, sales chewable XX% on same over its stride of the multivitamin, To has core quarter, all-time year-over-year for segment, multivitamin we franchise. an growth showcase
RxConnect full with in a access Aytu was program, quarter access Neos first the marked from newly our quarter which patient of formed This rebranded the consolidation Aytu patient programs.
RxConnect pharmacy prescription Neos additional a predictable the core novel marketplace enables any program hassles and advantage and products and access. substantial co-pays at commercially patient in leverage and gives continue legacy to affordable, dramatically have Through support onto and to enabled our platform the ability us higher pharmacy distinct to integrated. known prescribe and rate might legacy the network, now now assets our to are our patients than reduced drive the brands a their Rx refine ordinarily RxConnect for expansion refills we physicians bring a Aytu platform. way This nationwide be the program program on added is RxConnect have patient predictable, program with all this to simply have and We design innovative patients access covered are patients brands predictable. delivery, and When or efficient physicians economics Aytu us an This patients and anything but brands when RxConnect quite stands for achieved. out. co-pays our to game-changer a really the products. At time for branded favorable
quarter, prescriptions RxConnect, RxConnect integrating percentage made product pharmacies of a of excuse me, pleased portfolio quick through we're progress and this saw growth into network the we've as our During going the of full RX in we with the program.
our of with anticipated to through new the grow expect distribution an by Going driven expect to forward, and product of recently signed organic health agreement the across that OTC growth we through business, consumer manufacturer. e-commerce increasing OTC anticipate introductions. products, and medicines and pediatric prescription much the We and exclusive ADHD to launch sales division growth various see be revenue new
profitability to seen. pandemic. previous the people for of due is uptick that additional we When shopping forward. e-commerce period revenues of segment portion to remains growth e-commerce saw plan This that consumer transiently products $X still the as X% health last we Despite important year-over-year, online was year. very growth platform. grew of again, consumer has with platform last to For our acquisition growth driving and The products global continued as thus summer's even our notable quite we not should believe the previously year over the much when addition brands, purchasing peak costs We this our relative this levels summer, million. along level business grow scalable. high saw staying the e-commerce because home growth is large scale were going is health growth same and this onto over new the lower we last consumer to consumer And of this add organic
Turning now with I'll our start Healight. development to pipeline.
the Healight importantly, leading therapy endotracheal and is infected a respiratory reminder, an is this treated of of potentially study SARS-CoV-X have patients. and in X light treatment last believe mechanical days and infective reduces SARS-CoV-X hospitalized with is we improvement severe endpoint the remain demonstrated targeting and of from announced COVID-XX sham light a change Between As ventilated viral infections to significant journal Medical mechanically human We of platform the applications. at a study points been a mechanically tube clinical academic at outcomes cells, enroll for a Healight viral between to treatment. this newly load, treatment expected integrated XX ground-breaking all in year respiratory Center These first-in-class in patients in ventilated untreated initiate cellular endotracheal release cytokine efficacy aspirates patients. the global Barcelona, initially this and This publications from coronavirus Spain published quarter, in patients. to hospital catheter primary UVA the patients. data safety, conducted last for in endotracheal track The study We rights light-based - from be light with that and controlled effects is UVA on Cedars-Sinai ultraviolet X, technology evaluating with licensed ventilation. will load, data catheter, randomized aid on anti platform. healed that the reduction to day associated of We
line continued with influenza, first commercial applications we areas -- COVID, completion and we've to opportunity associated ventilator severe the for outside demonstrate treat other of The as calendar expect potential data the such to report top Healight Following XXXX. enrollment, in reported outside year to disease to pneumonia, of half the difficult infections. of data profound
of ventilator continue of planning excited first study Healight our exploring associated pneumonia. exploring in outside are depth are to We and already potential the COVID-XX,
get proof-of-concept to also this underway We quarter. study, expect that
chaired rupture Syndrome is or typically a that chemical ARXXX pediatric no dysection of rare in are the the these [Indiscernible]. pipeline the treating Vascular patients. those and patients VEDS. In genetic genetic and patient VEDS and of disease is targets childhood rupture have scientific consisting straightforward confirming rare the the approved mutation, There highlighted VED the board and disorder Ehlers-Danlos supporting bow currently the leading [Indiscernible]. if the has by groundbreaking rupture trial test X,XXX diagnosed Our arterial FDA who to it locating treatments we clinical pivotal with by the easily in of September, rare formation Hopkins, advisory study pediatric relates Dr. as VEDS. making for treatment VED and onset entity U.S. conducted enrollment aneurysm, a Hal new research approximately is and to coal VEDS. targeting experts by A Dietz of in diagnosed for ultimately in XAX genetic a date of approved, also ARXXX disease, characterized John announced ready of -- and
the as that We've desperately need of development identify execute the this plans, the with meetings study study the to continue frequent well-positioned for SAB and interaction With sites. as of this SAB, protocol is well treatment. numerous to patients on and ARXXX held as formation prospective we evolve Company the
of We study pursuing currently pivotal and one-to-one. half XXXX. patients reduction patients, goal calendar of of enrollment of this status referred as as the those the an FDA approximately events, each from dissections, We pseudoaneurysms. designation with and fatal the the and is prevent The launch non-fatal primary positive COLXAX randomized ARXXX are year a study, to of patients With a trial arterial endpoint with and then the this to of in beds. EMEA such plan receiving ruptures, of of or orphan XXX first drug
endpoints We with period. over background planning treatment analysis patients taking We're secondary and measures. beta study of and storm, ends imaging months month capturing interim expect of a like and patients an also on to every safety XX inclusive and X ARBs without meds standard blockers those
of fully and the XX, We the expect in study study to XXXX. first the XX half initiate in QX enroll of
are VEDS, identification, in Ehlers-Danlos, with additional also over patients, that, sight their instrumental the VEDS engaged movement, will with instrumental specifically have support community. of numerous to in on some are All highlights. -- these Ehlers-Danlos support overall Rich support and I of patient financial turn constantly organizations and And their the Rich. advocacy assisting us the VEDS helped patient group Annabelle's been society, the now call Challenge. for around and have We events VEDS including and fight highly with VEDS in
